A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic

Last updated: August 14, 2025
Sponsor: Sanofi
Overall Status: Completed

Phase

N/A

Condition

Dermatitis, Atopic

Allergy

Atopic Dermatitis

Treatment

N/A

Clinical Study ID

NCT05527964
OBS17350
U1111-1279-3216
  • Ages > 18
  • All Genders

Study Summary

Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24.

Description of the:

  • Change in disease activity after 16 and 24 weeks

  • Change in subject and family quality of life after 16 and 24 weeks

  • Change in sleep quality after 16 and 24 weeks

  • Change in anxiety after 16 and 24 weeks

  • Change in depression after 16 and 24 weeks

  • Safety and tolerability

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient eligible for Dupixent therapy of AD according to the current SPC andreimbursement criteria given by the SUKL

  • Signed informed consent

  • 18 years and older (study questionnaires are validated for this age group). Patientis able to follow the prescribed regimen, routine follow-up visits and to fill thequestionnaires

Exclusion

Exclusion Criteria:

  • Patient not eligible for Dupixent therapy of AD according to the current SPC andreimbursement criteria given by the SUKL.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Study Design

Total Participants: 146
Study Start date:
December 30, 2022
Estimated Completion Date:
June 16, 2025

Study Description

28 weeks

Connect with a study center

  • Investigational Site: Bulovka University Hospital

    Prague, 180 81
    Czechia

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.